Related Experiment Video
Updated: Jul 15, 2026
Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Postmenopausal tibolone therapy: biologic principles and applied clinical practice
1mnotelo@aol.com
Abstract:
Although the menopause is a generic physiologic event, its biology is variable and specific to a given individual. Genetically determined distribution and polymorphism of relevant hormone receptors, enzymes, and various cofactors are the biologic mechanisms controlling an individual's clinical response to endogenous and prescribed hormones. Advances in molecular biology have led to the development of newer pharmacologic agents that are tailored to meet specific therapeutic objectives, based on the hormonal biology of relevant organs. Tibolone, an analogue of the progestin, norethynodrel, is a drug with tissue-specific effects on receptors and enzymes that influences the synthesis and metabolism of endogenous estrogen, progesterone, and androgen. This is achieved via the intestinal bioconversion of tibolone into metabolites that have tissue-specific agonistic and/or antagonistic estrogenic (3alpha and 3beta hydroxytibolone) and progestogenic/androgenic (delta4 tibolone) properties. The postmenopausal synthesis and metabolism of estrogen and androgen are briefly reviewed with particular reference to sex steroid activity in various target organs. On the basis of this hormonal physiology, the clinical utility of tibolone is reviewed as a therapeutic agent for the treatment of the symptomatic menopause. The effects of tibolone on bone health and osteoporosis, cardiovascular disease, the breast, and the endometrium are summarized, and its role in clinical practice is reviewed.
Insights
Tibolone, a unique hormone therapy, offers tissue-specific benefits for menopausal symptoms by influencing estrogen, progesterone, and androgen activity. Its metabolites provide targeted effects, aiding in managing bone health, cardiovascular risks, and other menopausal concerns.
Area of Science:
- Endocrinology
- Pharmacology
- Molecular Biology
Background:
- Menopause biology varies individually due to genetic factors influencing hormone receptor and enzyme activity.
- Molecular biology advances enable targeted pharmacologic agents based on organ-specific hormonal biology.
- Tibolone, a progestin analogue, exhibits tissue-specific effects on hormone synthesis and metabolism.
Purpose of the Study:
- To review the clinical utility of tibolone for symptomatic menopause.
- To summarize tibolone's effects on bone health, cardiovascular disease, breast, and endometrium.
- To discuss tibolone's role in clinical practice based on hormonal physiology.
Main Methods:
- Review of postmenopausal estrogen and androgen synthesis and metabolism.
- Analysis of tibolone's bioconversion into tissue-specific active metabolites (3alpha/3beta hydroxytibolone, delta4 tibolone).
- Evaluation of tibolone's agonistic/antagonistic properties on estrogen, progesterone, and androgen receptors.
Main Results:
- Tibolone metabolites possess tissue-specific estrogenic, progestogenic, and androgenic properties.
- The drug influences endogenous sex steroid activity in target organs.
- Clinical utility is reviewed concerning menopausal symptom management.
Conclusions:
- Tibolone's unique mechanism offers targeted therapeutic benefits for menopausal symptoms.
- Its tissue-specific actions are crucial for managing bone health, cardiovascular aspects, and reproductive tissues.
- Tibolone represents a valuable therapeutic option in clinical practice for postmenopausal women.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
01:16Therapeutic Drug Monitoring: Overview and Classification
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:15Drugs that Stabilize Microtubules
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.